People · Operator
Named in public records as an officer, director or promoter · active 2009–2009 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Trubion Pharmaceuticals, Inc | — | Biotechnology | Series A | $10.0M | $361.5M | 2009 |
Scott Stromatt at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Scott Stromatt on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven Gillis | 1 | 23 |
| Peter Thompson | 1 | 16 |
| Patrick Heron | 1 | 11 |
| David Schnell | 1 | 7 |
| Kendall Mohler | 1 | 5 |
| Samuel R. Saks | 1 | 2 |
| Anders D. Hove | 1 | 2 |
| David A. Mann | 1 | 1 |
| Lee R. Brettman | 1 | 1 |
| Kathleen M. Deeley | 1 | 1 |
| Michelle Burris | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.